Spin-off of Alma Mater acquired by Amicus Therapeutics
The company MiaMed, spin-off of the University of Bologna, has been acquired by the multinational biotech giant Amicus Therapeutics. MiaMed aims to innovate medical research by promoting a new protein therapy for “CDKL5 syndrome”, a rare and degenerative disease. The therapy was developed by Elisabetta Ciani (pictured), from the Department of Biomedical and Neuromotor Sciences at Alma Mater.
This is an important step towards the realization and practical consequences of the results of research carried out at the University of Bologna. “It is a great satisfaction – says Professor Ciani – to be able to see real prospects of development for the important results obtained over years of research: the initial motivation and funding came from the families of sick children, gathered in associations at Italian and international level; all my research team members, with an average age of 35 years, worked with passion and strong dedication to the development of the initial idea, also with the contribution of the Medical University of Vienna.”
“The CDKL5 programme – says John Crowley, CEO of Amicus Therapeutics – is an important investment in our stated strategy to expand our biologics pipeline by integrating new, innovative technologies to develop first- and best-in-class therapies for patients who are in desperate need of new treatments. CDKL5 is a rare and devastating disease with no approved treatment. Most patients with CDKL5 have frequent seizures that begin shortly after birth. They experience severe impairment in neurological development, and many of them are unable to walk, talk or care for themselves. We are pleased to partner with the CDKL5 patient and medical community to elevate disease awareness as we advance towards a treatment”.